Navigation Links
New approach to anti-anxiety drugs

Researchers have found that lack of a brain protein makes mice notably less anxious and may extend the findings to humans with anxiety disorders. Anxiety is a natural human response to life,// but when it gets out of hand it can inhibit everyday behaviour and cause much suffering. Around 15 million people might have had the necessity for anxiety related treatment. The anti-anxiety drugs have always been very effective in such needy times. The major class is known as the benzodiazepines but these have the drawback of causing sedation that may make it hard to function. They also have the potential to cause addiction. Researchers at the University of North Carolina, and others, now report that they have found a potential new target for anti-anxiety drugs.

They've been looking at mice genetically altered so they don't produce a natural brain protein called protein kinase C. These mice seem to be more sensitive to the brain's own sedative molecules, known as neurosteroids. They are less fearful of heights and open spaces (a test of anxiety in mice). The researchers wonder if creating inhibitors for protein kinase C would be a useful way forward for treating anxiety in humans, providing an alternative to the benzodiazepines.


'"/>




Page: 1

Related medicine news :

1. Fresh approach to TB treatment
2. More signs to an approaching migraine attack
3. Gene enchances radiation therapy - A novel approach to fight cancer
4. Combined modality approach for effective treatment and enhanced survival in bile duct cancer
5. A new approach to vaginal hysterectomy
6. Multi targeted approach required for suicide prevention in adolescents
7. Mathematical approach to asthma
8. Trident approach reduces malaria in HIV patients
9. A Novel approach in Malaria treatment
10. Cancer drugs in development nearly doubled since 1995
11. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New approach anti anxiety drugs

Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 1RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 2RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 3RadioShack Partners With Seven Time Tour de France Winner Lance Armstrong to Form New Cycling Team in 2010 52566 4Injection Reverses Heart Attack Damage 4771 1Injection Reverses Heart Attack Damage 4771 2Injection Reverses Heart Attack Damage 4771 3Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 1Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 2Study in this Week 26apos 3Bs Issue of Cell Finds Injected Growth Factor Spurs Heart Regeneration 52563 3
Other Medicine Technology:Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 2Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 3Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 4Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 5Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated 6Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 2Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 3Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 4Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 5Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions 6